|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sivridis E, Giatromanolaki A, Gatter KC,
Harris AL and Koukourakis MI: Tumor and Angiogenesis Research
Group: Association of hypoxia-inducible factors 1alpha and 2alpha
with activated angiogenic pathways and prognosis in patients with
endometrial carcinoma. Cancer. 95:1055–1063. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sakuragi N, Ohkouchi T, Hareyama H, Ikeda
K, Watari H, Fujimoto T, Kuwabara M, Yamamoto R, Sagawa T, Fujino T
and Fujimoto S: Bcl-2 expression and prognosis of patients with
endometrial carcinoma. Int J Cancer. 79:153–158. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wen SY, Zhang LN, Yang XM, Zhang YL, Ma L,
Ge QL, Jiang SH, Zhu XL, Xu W, Ding WJ, et al: LRG1 is an
independent prognostic factor for endometrial carcinoma. Tumour
Biol. 35:7125–7133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saarelainen SK, Staff S, Peltonen N,
Lehtimäki T, Isola J, Kujala PM, Vuento MH and Mäenpää JU:
Endoglin, VEGF and its receptors in predicting metastases in
endometrial carcinoma. Tumour Biol. 35:4651–4657. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Honkavuori-Toivola M, Talvensaari-Mattila
A, Soini Y, Turpeenniemi-Hujanen T and Santala M: Immunoreactivity
for TIMP-2 is associated with a favorable prognosis in endometrial
carcinoma. Tumour Biol. 33:935–941. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rhodes J, York RD, Tara D, Tajinda K and
Druker BJ: CrkL functions as a nuclear adaptor and transcriptional
activator in Bcr-Abl-expressing cells. Exp Hematol. 28:305–310.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feller SM: Crk family adaptors-signalling
complex formation and biological roles. Oncogene. 20:6348–6371.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fidler IJ and Kripke ML: Genomic analysis
of primary tumors does not address the prevalence of metastatic
cells in the population. Nat Genet. 34:232003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hoeve J, Morris C, Heisterkamp N and
Groffen J: Isolation and chromosomal localization of CRKL, a human
crk-like gene. Oncogene. 8:2469–2474. 1993.PubMed/NCBI
|
|
11
|
ten Hoeve J, Kaartinen V, Fioretos T,
Haataja L, Voncken JW, Heisterkamp N and Groffen J: Cellular
interactions of CRKL, and SH2-SH3 adaptor protein. Cancer Res.
54:2563–2567. 1994.PubMed/NCBI
|
|
12
|
Beroukhim R, Mermel CH, Porter D, Wei G,
Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J,
Urashima M, et al: The landscape of somatic copy-number alteration
across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Senechal K, Halpern J and Sawyers CL: The
CRKL adaptor protein transforms fibroblasts and functions in
transformation by the BCR-ABL oncogene. J Biol Chem.
271:23255–23261. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van't Veer LJ, Dai H, van de Vijver MJ, He
YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ,
Witteveen AT, et al: Gene expression profiling predicts clinical
outcome of breast cancer. Nature. 415:530–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin F, Chengyao X, Qingchang L, Qianze D,
Enhua W and Yan W: CRKL promotes lung cancer cell invasion through
ERK-MMP9 pathway. Mol Carcinog. (54 Suppl 1). E35–E44. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Dong QZ, Fu L, Stoecker M, Wang E
and Wang EH: Overexpression of CRKL correlates with poor prognosis
and cell proliferation in non-small cell lung cancer. Mol Carcinog.
52:890–899. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ali RH and Rouzbahman M: Endometrial
stromal tumours revisited: An update based on the 2014 WHO
classification. J Clin Pathol. 68:325–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cikos S, Bukovská A and Koppel J: Relative
quantification of mRNA: Comparison of methods currently used for
real-time PCR data analysis. BMC Mol Biol. 8:1132007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Buhtoiarova TN, Brenner CA and Singh M:
Endometrial carcinoma: Role of current and emerging biomarkers in
resolving persistent clinical dilemmas. Am J Clin Pathol. 145:8–21.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang L, Yan L, Cao M, Zhang H, Li C, Bai
Y, Yu P, Li M and Zhao X: SPAG9 promotes endometrial carcinoma cell
invasion through regulation of genes related to the
epithelial-mesenchymal transition. Eur J Gynaecol Oncol.
37:312–319. 2016.PubMed/NCBI
|
|
21
|
Lian X, Jiao Y, Yang Y, Wang Z, Xuan Q,
Liu H, Lu S, Wang Z, Liu Y, Li S, et al: CrkL regulates
SDF-1-induced breast cancer biology through balancing Erk1/2 and
PI3K/Akt pathways. Med Oncol. 32:4112015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lv S, Qin J, Yi R, Coreman M, Shi R, Kang
H and Yao C: CrkL efficiently mediates cell proliferation,
migration, and invasion induced by TGF-β pathway in glioblastoma. J
Mol Neurosci. 51:1046–1051. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nosaka Y, Arai A, Miyasaka N and Miura O:
CrkL mediates Ras-dependent activation of the Raf/ERK pathway
through the guanine nucleotide exchange factor C3G in hematopoietic
cells stimulated with erythropoietin or interleukin-3. J Biol Chem.
274:30154–30162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Segovis CM, Schoon RA, Dick CJ, Nacusi LP,
Leibson PJ and Billadeau DD: PI3K links NKG2D signaling to a CrkL
pathway involved in natural killer cell adhesion, polarity, and
granule secretion. J Immunol. 182:6933–6942. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao T, Miao Z, Wang Z, Xu Y, Wu J, Liu X,
You Y and Li J: Overexpression of CRKL correlates with malignant
cell proliferation in breast cancer. Tumour Biol. 34:2891–2897.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fu L, Dong Q, Xie C, Wang Y and Li Q: CRKL
protein overexpression enhances cell proliferation and invasion in
pancreatic cancer. Tumour Biol. 36:1015–1022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Singer CF, Hudelist G, Lamm W, Mueller R,
Handl C, Kubista E and Czerwenka K: Active (p)CrkL is overexpressed
in human malignancies: Potential role as a surrogate parameter for
therapeutic tyrosine kinase inhibition. Oncol Rep. 15:353–359.
2006.PubMed/NCBI
|
|
28
|
Kim YH, Kwei KA, Girard L, Salari K, Kao
J, Pacyna-Gengelbach M, Wang P, Hernandez-Boussard T, Gazdar AF,
Petersen I, et al: Genomic and functional analysis identifies CRKL
as an oncogene amplified in lung cancer. Oncogene. 29:1421–1430.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fathers KE, Bell ES, Rajadurai CV, Cory S,
Zhao H, Mourskaia A, Zuo D, Madore J, Monast A, Mes-Masson AM, et
al: Crk adaptor proteins act as key signaling integrators for
breast tumorigenesis. Breast Cancer Res. 14:R742012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Chen X, Li P, Su L, Yu B, Cai Q,
Li J, Yu Y, Liu B and Zhu Z: CRKL promotes cell proliferation in
gastric cancer and is negatively regulated by miR-126. Chem Biol
Interact. 206:230–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Quddus M Ruhul, Latkovich P, Castellani
WJ, Sung C James, Steinhoff MM, Briggs RC and Miranda RN:
Expression of cyclin D1 in normal, metaplastic, hyperplastic
endometrium and endometrioid carcinoma suggests a role in
endometrial carcinogenesis. Arch Pathol Lab Med. 126:459–463.
2002.PubMed/NCBI
|
|
32
|
Cassia R, Moreno-Bueno G,
Rodriguez-Perales S, Hardisson D, Cigudosa JC and Palacios J:
Cyclin E gene (CCNE) amplification and hCDC4 mutations in
endometrial carcinoma. J Pathol. 201:589–595. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
González-Rodilla I, Verna V, Muñoz AB,
Estévez J, Boix M and Schneider J: Expression of the
apoptosis-related genes Bcl-2 and p53 in clinical samples from
endometrial carcinoma patients. Anticancer Res. 31:4191–4193.
2011.PubMed/NCBI
|
|
34
|
Porichi O, Nikolaidou ME, Apostolaki A,
Tserkezoglou A, Arnogiannaki N, Kassanos D, Margaritis L and
Panotopoulou E: BCL-2, BAX and P53 expression profiles in
endometrial carcinoma as studied by real-time PCR and
immunohistochemistry. Anticancer Res. 29:3977–3982. 2009.PubMed/NCBI
|
|
35
|
Pallares J, Martinez-Guitarte JL, Dolcet
X, Llobet D, Rue M, Palacios J, Prat J and Matias-Guiu X: Survivin
expression in endometrial carcinoma: A tissue microarray study with
correlation with PTEN and STAT-3. Int J Gynecol Pathol. 24:247–253.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takai N, Miyazaki T, Nishida M, Nasu K and
Miyakawa I: Survivin expression correlates with clinical stage,
histological grade, invasive behavior and survival rate in
endometrial carcinoma. Cancer letters. 184:105–116. 2002.
View Article : Google Scholar : PubMed/NCBI
|
